Compare AbbVie Inc (ABBV) vs InMode Ltd (INMD) Price & Performance

AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.

The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.

INMD trades at $14.60, down 1.35% on the day, with mixed technical signals showing bullish moving averages but neutral oscillators. The company maintains strong profitability with 77.84% gross margins and 23.27% net income margins, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited buyout proposal at $16.20 per share and multiple securities fraud investigations announced in early July 2026.

The stock appears undervalued with a P/E of 10.81 and EV/EBITDA of 3.81, but faces near-term headwinds from legal investigations and earnings volatility. Analyst consensus sits at Hold with a $16.50 price target, representing 13% upside potential from current levels, though the ongoing legal scrutiny creates uncertainty for investors.